Novel extended release budesonide formulation for treatment of ulcerative colitis
暂无分享,去创建一个
[1] A. Griffiths,et al. Oral budesonide for induction of remission in ulcerative colitis. , 2015, The Cochrane database of systematic reviews.
[2] G. Kaplan,et al. Budesonide for induction of remission in Crohn's disease. , 2015, The Cochrane database of systematic reviews.
[3] M. Sans,et al. Oral locally active steroids in inflammatory bowel disease. , 2013, Journal of Crohn's & colitis.
[4] A. Nicholls,et al. Bioavailability profile of Uceris MMX extended-release tablets compared with Entocort EC capsules in healthy volunteers , 2013, The Journal of international medical research.
[5] S. Travis,et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study , 2013, Gut.
[6] S. Vermeire,et al. Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management , 2012 .
[7] R. Bagin,et al. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. , 2012, Gastroenterology.
[8] L. Kupčinskas,et al. 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial. , 2011, Journal of Crohn's & colitis.
[9] S. Danese,et al. Ulcerative colitis. , 2011, The New England journal of medicine.
[10] J. Stein,et al. Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left‐sided ulcerative colitis , 2010, Alimentary pharmacology & therapeutics.
[11] F. Nagy,et al. Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis. , 2010, Journal of Crohn's & colitis.
[12] G. Fiorino,et al. New drug delivery systems in inflammatory bowel disease: MMX and tailored delivery to the gut. , 2010, Current medicinal chemistry.
[13] A. Kornbluth,et al. Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee , 2010, The American Journal of Gastroenterology.
[14] G. D'Haens. The practical use of steroids in inflammatory bowel disease , 2006 .
[15] M. Brunner,et al. Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation. , 2006, British journal of clinical pharmacology.
[16] H. Eichler,et al. Colonic spread and serum pharmacokinetics of budesonide foam in patients with mildly to moderately active ulcerative colitis , 2005, Alimentary pharmacology & therapeutics.
[17] A. Francavilla,et al. A New Oral Delivery System for 5‐ASA: Preliminary Clinical Findings for MMX , 2005, Inflammatory bowel diseases.
[18] A. Otley,et al. Budesonide for induction of remission in Crohn's disease. , 2005, The Cochrane database of systematic reviews.
[19] T. Andersson,et al. Pharmacokinetics of Budesonide (Entocort™ EC) Capsules for Crohn’s Disease , 2004, Clinical pharmacokinetics.
[20] S. Hanauer,et al. Treatment of inflammatory bowel disease: safety and tolerability issues. , 2003, The American journal of gastroenterology.
[21] F. Manguso,et al. Oral beclomethasone dipropionate in patients with mild to moderate ulcerative colitis: A dose-finding study , 2001, Advances in therapy.
[22] S. Hanauer,et al. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group. , 1998, Gastroenterology.
[23] Å. Danielsson,et al. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. , 1996, Gastroenterology.
[24] R. Modigliani,et al. Comparison of budesonide and 5‐aminosalicylic acid enemas in active distal ulcerative colitis , 1995, Alimentary pharmacology & therapeutics.
[25] Å. Danielsson,et al. A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis. , 1987, Scandinavian journal of gastroenterology.
[26] C. FordAlexander,et al. ULCERATIVE colitis. , 1997, Journal of the American Medical Association.